Physician profile
Giuseppe Militello
NPI 1558381681
$7,568.68
in general payments reported to CMS, 2019-2025
40 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.89 · 2021: $988 · 2022: $610 · 2023: $1,340 · 2024: $2,612 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,743 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,742.51 |
| Education | $199.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $897.63 | 2021-2025 | Winlevi, Absorica Ld |
| Abbvie INC. | $833.36 | 2021-2025 | |
| Janssen Biotech, INC. | $709.12 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $668.93 | 2021-2025 | |
| Lilly USA, LLC | $518.09 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $491.71 | 2021-2025 | Opzelura |
| Pfizer INC. | $426.01 | 2021-2025 | |
| Leo Pharma INC. | $421.87 | 2021-2025 | Adbry, Anzupgo |
| Verrica Pharmaceuticals INC. | $412.18 | 2023-2024 | Ycanth |
| Ucb, INC. | $239.21 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $196.17 | 2023-2024 | Zoryve |
| Amgen INC. | $194.09 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $188.07 | 2022-2025 | |
| Journey Medical Corporation | $179.63 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $167.93 | 2022-2025 | Cabtreo, Targretin, Jublia |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $143.02 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $123.72 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $94.85 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Janssen Scientific Affairs, LLC | $84.42 | 2021 | |
| Kerecis Limited | $56.79 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Regeneron Healthcare Solutions, INC. | $52.82 | 2024-2025 | Libtayo |
| Sensus Healthcare, INC. | $51.47 | 2024 | |
| Blueprint Medicines Corporation | $46.76 | 2024-2025 | Ayvakit |
| Mayne Pharma Commercial LLC | $44.37 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.46 | 2024 | Spevigo |
| Astrazeneca Pharmaceuticals LP | $35.15 | 2023-2024 | Saphnelo |
| Biofrontera INC. | $30.97 | 2025 | |
| Merz North America, INC. | $24.12 | 2023 | Xeomin |
| Dermira, INC. | $22.53 | 2021 | |
| Almirall LLC | $20.70 | 2022 | |
| Springworks Therapeutics, INC. | $20.07 | 2025 | Gomekli |
| Helsinn Therapeutics (U.S.), INC. | $18.45 | 2025 | Valchlor |
| Kyowa Kirin, INC. | $18.10 | 2025 | |
| Botanix Sb INC | $17.83 | 2025 | Sofdra |
| Allergan, INC. | $17.51 | 2020 | |
| Revance Therapeutics, INC. | $15.33 | 2024 | Daxxify |
| Strata Skin Sciences, INC. | $15.22 | 2024 | Xtrac |
| Lnhc, INC | $13.84 | 2025 | Zelsuvmi |
| Allegis Pharmaceuticals, LLC | $12.47 | 2022 | |
| Organon LLC | $7.71 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giuseppe Militello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.